An interpretive history of the cholesterol controversy, part IV: The 1984 Coronary Primary Prevention Trial ends it - Almost

Journal of Lipid Research

Volumn 47, Issue 1, 2006, Pages 1-14

  Steinberg, Daniel ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cholestyramine; Coronary heart disease; National Cholesterol Education Program

Indexed keywords

BILE ACID; CHOLESTEROL; CLOFIBRATE; COLESTYRAMINE;

ATHEROGENESIS; CARDIOTOXICITY; CHOLESTEROL BLOOD LEVEL; CONSENSUS; CONSENSUS DEVELOPMENT; CORONARY ARTERY ATHEROSCLEROSIS; DRUG CYTOTOXICITY; EDUCATION PROGRAM; HEALTH PROGRAM; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; LOW FAT DIET; MEDICAL RECORD; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SCREENING TEST; STATISTICAL SIGNIFICANCE; ANIMAL; ATHEROSCLEROSIS; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; CORONARY ARTERY DISEASE; ETHICS; HISTORY; UNITED STATES;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL; CLINICAL TRIALS; CONSENSUS DEVELOPMENT CONFERENCES, NIH; CORONARY DISEASE; HISTORY, 20TH CENTURY; HUMANS; MODELS, CARDIOVASCULAR; UNITED STATES;

EID: 30844449429     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R500014-JLR200     Document Type: Review

References (44)

1. Steinberg, D. 2004. An interpretive history of the cholesterol controversy. Part I. J. Lipid Res. 45: 1583-1593.
2. Steinberg, D. 2005. An interpretive history of the cholesterol controversy. Part II. The early evidence linking hypercholesterolemia to coronary disease in humans. J. Lipid Res. 46: 179-190.
3. Steinberg, D. 2005. An interpretive history of the cholesterol controversy. Part III. Mechanistically defining the role of hyperlipidemia. J. Lipid Res. 46: 2037-2051.
4. Fredrickson, D. S., R. I. Levy, and R. S. Lees. 1967. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders. N. Engl. J. Med. 276: 34-42.
5. Fredrickson, D. S., R. I. Levy, and R. S. Lees. 1967. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders. N. Engl. J. Med. 276: 94-103.
6. Fredrickson, D. S., R. I. Levy, and R. S. Lees. 1967. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders. N. Engl. J. Med. 276: 215-225.
7. Gofman, J. W., F. T. Lindgren, and H. Elliott. 1949. Ultracentrifugal studies of lipoproteins of human serum. J. Biol. Chem. 179: 973-979.
8. Gofman, J. W., F. Lindgren, H. Elliott, W. Mantz, J. Hewitt, and V. Herring. 1950. The role of lipids and lipoproteins in atherosclerosis. Science. 111: 166-171.
9. Fredrickson, D. S. 1968. The field trial: some thoughts on the indispensable ordeal. Bull. N. Y. Acad. Med. 44: 985-993.
10. Steinberg, D. 1975. Planning the type II coronary primary prevention trial of the lipid research clinics (U. S. A.). Adv. Exp. Med. Biol. 63: 417-426.
11. Diet-Heart Review Panel of the National Heart Institute. 1969. Mass Field Trials of the Diet-Heart Question. American Heart Association, Dallas, TX.
12. Buchwald, H., R. L. Varco, J. P. Matts, J. M. Long, L. L. Fitch, G. S. Campbell, M. B. Pearce, A. E. Yellin, W. A. Edmiston, R. D. Smink, Jr., et al. 1990. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N. Engl. J. Med. 323: 946-955.
13. Buchwald, H., R. L. Varco, J. R. Boen, S. E. Williams, B. J. Hansen, C. T. Campos, G. S. Campbell, M. B. Pearce, A. E. Yellin, W. A. Edmiston, et al. 1998. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. Arch. Intern. Med. 158: 1253-1261.
14. Dewar, H. A., and M. F. Oliver. 1971. Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials. BMJ. 4: 784-786.
15. Cooper, J., H. Geizerova, and M. F. Oliver. 1975. Clofibrate and gallstones (Letter). Lancet. 1: 1083.
16. Oliver, M. F. 1978. Cholesterol, coronaries, clofibrate and death. N. Engl. J. Med. 299: 1360-1362.
17. Hunninghake, D. and J. Probstfield. 1977. Drug treatment of hyperlipoproteinemia. In Hyperlipidemia - Diagnosis and Treatment. B. Rifkind and R. I. Levy, editors. Grune and Stratton, New York.
18. Lipid Research Clinics Coronary Primary Prevention Trial. 1984. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J. Am. Med. Assoc. 251: 365-374.
19. Pinckney, E. R., and R. L. Smith. 1987. Statistical analysis of lipid research clinics program. Lancet. 1: 503-504.
20. The Coronary Drug Project Research Group. 1972. The Coronary Drug Project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. J. Am. Med. Assoc. 220: 996-1008.
21. 1971. Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region. BMJ. 4: 767-775.
22. Gould, A. L., J. E. Rossouw, N. C. Santanello, J. F. Heyse, and C. D. Furberg. 1998. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation. 97: 946-952.
23. Simons, L. A. 1984. The lipid hypothesis is proven. Med. J. Aust. 140: 316-317.
24. Podell, R. N. 1984. Coronary disease prevention: proof of the anticholesterol pudding. Postgrad. Med. 75: 193-196.
25. Oliver, M. F. 1984. Hypercholesterolaemia and coronary heart disease: an answer. Br. Med. J. (Clin. Res. Ed.). 288: 423-424.
26. Mann, G. V. 1985. Coronary heart disease - "doing the wrong thing." Nutr. Today. August/September: 12-14.
27. Frick, M. H., O. Elo, K. Haapa, O. P. Heinonen, P. Heinsalmi, P. Helo, J. K. Huttunen, P. Kaitaniemi, P. Koskinen, V. Manninen, et al. 1987. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317: 1237-1245.
28. Virkkunen, M. 1979. Serum cholesterol in antisocial personality. Neuropsychobiology. 5: 27-30.
29. Virkkunen, M., and H. Penttinen. 1984. Serum cholesterol in aggressive conduct disorder: a preliminary study. Biol. Psychiatry. 19: 435-439.
30. Wysowski, D. K., and T. P. Gross. 1990. Deaths due to accidents and violence in two recent trials of cholesterol-lowering drugs. Arch. Intern. Med. 150: 2169-2172.
31. The Scandinavian Simvastatin Survival Study. 1994. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344: 1383-1389.
32. Long-Term Intervention with Pravastatin in Ischaemic Disease Study Group. 1998. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339: 1349-1357.
33. MRC/BHF Heart Protection Study. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 360: 7-22.
34. Nestel, P. J. 1984. Time to treat cholesterol seriously. Aust. N. Z. J. Med. 14: 198-199.
35. Oliver, M. F. 1985. Consensus or nonsensus conferences on coronary heart disease. Lancet. 1: 1087-1089.
36. Kolata, G. 1985. Heart panel's conclusions questioned. Science. 227: 40-41.
37. Moore, T. J. 1989. The cholesterol myth. Atlantic. September: 37-70.
38. Expert Panel. 1988. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch. Intern. Med. 148: 36-69.
39. Cleeman, J. I., and C. Lenfant. 1998. The National Cholesterol Education Program: progress and prospects. J. Am. Med. Assoc. 280: 2099-2104.
40. Cleeman, J. I. 1989. National Cholesterol Education Program. Overview and educational activities. J. Reprod. Med. 34: 716-728.
41. Norum, K. R. 1978. Some present concepts concerning diet and prevention of coronary heart disease. Nutr. Metab. 22: 1-7.
42. Fine, R. A. 1972. The Great Drug Deception: The Shocking Story of MAR/29. Stein and Day, New York.
43. Shepherd, J., S. M. Cobbe, I. Ford, C. G. Isles, A. R. Lorimer, P. W. Macfarlane, J. H. McKillop, and C. J. Packard. 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333: 1301-1307.
44. Sacks, F. M., M. A. Pfeffer, L. A. Moye, J. L. Rouleau, J. D. Rutherford, T. G. Cole, L. Brown, J. W. Warnica, J. M. Arnold, C. C. Wun, et al. 1996. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335: 1001-1009.